BIIB Stock Recent News

The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease candidate.

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer's disease. Fast Track designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and address unmet medical needs.

CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation plan in Massachusetts. The move centralizes Biogen's presence in Kendall Square, integrating Biogen's research and development and technical operations teams alongside its global and North American commercial organizations into a co-located innovation hub. Scheduled to open when Biogen celebrates its 50th anniversary in 2028, the new state-of-the-art facility will commemorate five decades of excellence in scientific discovery, clinical development, and delivering innovative new treatments.

Biogen Inc. (NASDAQ:BIIB ) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Company Participants Priya Singhal - Head of Development Conference Call Participants Paul Matteis - Stifel Paul Matteis Great. Good morning, everybody.

Biogen (BIIB) reported earnings 30 days ago. What's next for the stock?

Sales of Biogen's BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is resulting in declining total revenues. Biogen's total revenues declined 2% in 2024.

BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients.

CAMBRIDGE, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to placebo in adult kidney transplant recipients diagnosed with late antibody-mediated rejection (AMR). TRANSCEND is designed to enroll approximately 120 kidney transplant recipients with late AMR.

Biogen Inc. (NASDAQ:BIIB ) Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ET Company Participants Alisha Alaimo - President of North America Conference Call Participants Marc Goodman - Leerink Partners Marc Goodman Thank you very much for joining us for the next session at the Leerink Global Healthcare Conference. I'm Marc Goodman, one of the biopharma analyst, and we're lucky to have Biogen with us here, Alisha Alaimo, who is the President of North America.

If you're one of the over 4 Million Americans set to retire this year, you may want to pay attention.